Device for pressure measurement and drug introduction into blood vessel aneurism

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly to vascular and endovascular surgery, and can be used to assess the state of an isolated aneurismal sac after a stent graft implantation by measuring a pressure inside the sac, as well as for introducing drugs into the blood vessel aneurism as it may be required. The device for pressure measurement in the isolated cavity of the aneurismal sac and for drug introduction into the blood vessel aneurism is configured as a hollow tube. The tube has side holes and is configured to reshape when inserted into the aneurism, to fill its inner space circumferentially, to attach by a two-piece hollow tube to a pressure sensor to measure a pressure between the vascular wall and the wall of the stent graft implanted into the blood vessel, as well as to introduce drugs by means of the above two-piece hollow tube. The tube is made of a viscoelastic absorbable material and spiral-shaped.

EFFECT: invention enables solving a set of challenges: saving the manufacturing expenses, simplifying the course of the surgical intervention, measuring the pressure, introducing the drugs, improving the immediate and remote results by ensured thrombosing of the aneurismal sac.

5 cl, 3 dwg

 

The invention relates to medicine, in particular to vascular and endovascular surgery, and can be used to assess the status of the isolated aneurysmal SAC after implantation of the stent-graft by measuring the pressure inside the bag, as well as for the introduction of medicinal substances in an aneurysm of a blood vessel as needed.

Known stent-graft (patent US No. 5716365, A61F, 1998), providing internal insulation of an aneurysm of a blood vessel. The disadvantage of this stent-graft is the inability to assess the state of the isolated aneurysmal SAC after implantation (in particular, the measurement of the pressure inside the bag and drug administration as required).

A device for measuring the pressure and the introduction of medicinal substances in the form of a catheter with side holes, which is the closest technical solution for the problem (patent US No. 5037403, AM 25/00, 1991).

A disadvantage of the known technical solution is the impossibility of carrying out assessment of the status of the isolated space aneurysmal SAC between the vascular wall and the wall of the aneurysm stent-graft after he plantacii.

The closest to the claimed invention is a device for measuring the pressure in an isolated simple�ansto aneurysmal SAC and for the introduction of medicinal substances in an aneurysm of a blood vessel, made in the form of a hollow nitinol tube with side holes. The tube is made with the ability to change form when introduced into the aneurysm and filling the entire internal space of the circumference, with the possibility of connection through a detachable hollow tube to the pressure sensor for measuring the pressure between the vascular wall and the wall is implanted in a blood vessel stent-graft and also with the ability to supply medicinal substances by specified split hollow tube (patent RU №2521833 C2, AM 25/00, 2014).

The disadvantages of the known technical solutions are:

- the complexity of implantation of said device;

- the impossibility of removal of said device after its use;

- the high cost and complexity of manufacturing, because due to initially set during the manufacture of the device dimensions and shape, the device may be used to install in a specific aneurysm and the device it is possible to set the stent-graft also strictly specified size.

The purpose of the invention is the exception these disadvantages and to develop a versatile device that provides assessment of isolated space aneurysmal SAC by pressure measurement and drug administration in an aneurysm of a blood vessel after implantation-graft.

This is achieved in that the device for measuring the pressure in the isolated space of the aneurysmal SAC and to the introduction of drugs into an aneurysm of a blood vessel is made in the form of a hollow tube. The tube has a lateral opening and being configured to change shape when introduced into the aneurysm and filling the entire internal space of the circumference, with the possibility of connection through a detachable hollow tube to the pressure sensor for measuring the pressure between the vascular wall and the wall is implanted in a blood vessel stent-graft and also with the ability to supply medicinal substances by specified split hollow tube. The tube is made of elastic resorbable material and twisted in a spiral.

The invention is illustrated by drawings, where

Fig.1 shows an embodiment of a device for pressure measurement and drug administration in advance of the vessel (a tube is twisted in the form of a cylinder; b - tube is twisted in the form of a cone; in the twisted tube has a barrel-shaped);

Fig.2 shows the device before installation vessel into the aneurysm;

Fig.3 shows the device located in the vessel, with the stent-graft.

In the claimed invention, the device 1 (Fig.1) for measuring the pressure and the introduction of�need drugs made from a hollow tube with 2 open or closed (deaf) end end (not shown) and with side holes 3. The hollow tube 2 is made of elastic resorbable material, for example from polylactate. The tube 2 is twisted in a spiral, which can have different shapes (cylinder, cone, barrel, etc.), and has the ability, through a detachable hollow tube 4, to be connected to a pressure measuring sensor (not shown) and also has the ability to supply drugs using the same previously specified detachable hollow tube 4.

The device is used as follows.

Before the introduction of the aorta diagnosed with an aneurysm in a blood vessel. The device 1, by stretching due to the elastic properties of the material, straighten (extend) and placed on the conductor 5 (Fig.2). Then enter one of the known methods in an aneurysm of a blood vessel. Once the device 1 is in the area of the aneurysmal SAC, the conductor 5 is removed from the hollow tube 2. Thanks to the implementation of the device of elastic material, the hollow tube 2 tries to return to its original shape and occupies the entire interior of the aneurysm in her circle. Next, to isolate the aneurysmal SAC inside helically coiled hollow tube 2 is placed stent graft 6. The implantation of the stent graft 6 is produced by well-known methods, setting it in this way (Fig.3) so that after implantation of the stent�-graft 6 shows a device 1 for measuring the pressure in the isolated space of the aneurysmal SAC and to the introduction of drugs into an aneurysm of a blood vessel located between the aneurysm wall 7 and the wall stent-graft 6. To assess the condition of the aneurysmal SAC after the implantation of stent-graft 6, spirally coiled hollow tube 2 is connected to the sensor for measuring the pressure (not shown) by means of detachable hollow tube 4 and through the side openings 3 formed in the tube 2, measure the pressure in the isolated aneurysmal SAC, and, if necessary, through the hollow split tube 4 serves a medicinal substance, for example tremulously glue. Then a hollow split tube 4 is detached from helically coiled tube 2, and a spirally coiled tube 2 remains in the patient's body for a while before its complete resorption.

Thus, the implementation of the device for measuring the pressure and the introduction of drugs into an aneurysm of a blood vessel in the form of a hollow tube twisted in a spiral of elastic resorbable material enables you to solve a number of tasks: saving money on production devices, simplification of the operational intervention, measurement of pressure, flow of drugs, improving the immediate and long-term results guaranteed by thrombosis of the aneurysmal SAC.

1. Device for measuring the pressure in the isolated space of the aneurysmal SAC and for the introduction of medicinal substances into the aneurysm� blood vessel, made in the form of a hollow tube, wherein the tube has a lateral opening and being configured to change shape when introduced into the aneurysm and filling the entire internal space of the circumference, with the possibility of connection through a detachable hollow tube to the pressure sensor for measuring the pressure between the vascular wall and the wall is implanted in a blood vessel stent-graft and also with the ability to supply medicinal substances by specified split hollow tube, wherein the tube is made of elastic resorbable material and twisted in a spiral.

2. The device according to claim 1, characterized in that twisted into the shape of a spiral pipe has the shape of a cylinder.

3. The device according to claim 1, characterized in that twisted into the shape of a spiral pipe has the shape of a cone.

4. The device according to claim 1, characterized in that twisted in the form of a spiral tube has a barrel shape.

5. Device according to any one of claims.1-4, characterized in that the front end of the hollow tube is made closed.



 

Same patents:

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine, particularly to treating bronchopulmonary dysplasia. A method involves administering an effective amount of citrulline into the patient. What is also presented is a pharmaceutical composition applicable for intravenous administration, containing a pharmaceutically acceptable carrier and an amount of citrulline effective for increasing blood plasma citrulline. The level is measured by comparing plasma citrulline in the patient under treatment to that in the patient having no bronchopulmonary dysplasia. The given composition is presented for producing a preparation for injections.

EFFECT: inventions provide the effective treatment of bronchopulmonary dysplasia by the polycomponent effect of citrulline on the disease process.

11 cl, 8 dwg, 2 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine. A drug delivery control unit comprises a user's interface configured to receive input data. The input data comprises patient's data and/or drug data and/or vascular access device data. A sensor is configured to measure a liquid pressure rate in a liquid delivery canal, which is used to deliver the drug to a patient's infusion site by means of the vascular access device. A processor is configured to assess a model state of the infusion site on the basis of the pressure rate in the liquid delivery canal and the input data. An output device notifies, supplies an urgent signal and/or a graphic/digital indication if the assessed model state of the infusion site and the liquid pressure rate in the liquid delivery canal to the infusion site testifies to infiltration. There are disclosed a method for controlling the drug delivery and a computer-readable carrier containing commands for implementing the method.

EFFECT: inventions enable detecting the infiltration condition and notify about the same.

16 cl, 6 dwg, 1 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to urology. A stent representing a threaded metal spiral is installed into the prostatic urethra with the use of a guide and the Foley catheter. The hollow rigid metal guide is curved along the urethral flexure, provided with a handle on the outer end and an inner thread on the inner end. The spiral stent is attached to the guide, and the Foley catheter is inserted therein. The device is installed into the prostatic urethra. The Foley catheter balloon is emptied. The catheter is removed. The guide is detached from the spiral and removed from the urethra.

EFFECT: method simplifies the delivery and provides the accurate installation of the urethral stent into the prostatic urethra by avoiding the necessity of using endoscopic equipment with a simple procedure for the guide and catheter removal from the urethra.

3 dwg

FIELD: medicine.

SUBSTANCE: endovascular embolisation of the uterine arteries are approached through a radial artery. Khair diagnostic catheter is inserted at the bifurcation of the abdominal aorta. Khair catheter tip is rotated to the right to provides sequential catheterisation of the right internal iliac and uterine arteries. That is followed by embolisation of the right uterine artery. Thereafter, Khair diagnostic catheter is pulled back up to the bifurcation of the abdominal aorta, and its tip is rotated to the left. That is followed by sequential catheterisation of the left internal iliac and uterine arteries. That is followed by embolisation of the left uterine artery. Khair diagnostic catheter and introducer are removed, and haemostasis is performed.

EFFECT: method enables reducing the length of the procedure, a radiation-absorbed dose and a rate of the following complications; it promotes early mobilisation of the patient after the procedure.

1 ex

FIELD: medicine.

SUBSTANCE: invention relates to medical equipment, namely, to means of endovascular device positioning. An adaptor contains an element, which has two ends and an internal lumen, made in such a way that when one end is connected to a catheter, and the other end is connected to a syringe, liquid from the syringe flows through the lumen into the catheter. A metal ring is located along the internal lumen of the element fully inside the said element in such a way that the metal ring is brought into electric contact with the liquid, when it flows from the syringe into the catheter, with the metal ring being connected to the external side of the element by means of insulated electric connection.

EFFECT: application of the invention makes it possible to increase the reliability of connection of the catheter and the syringe.

18 cl, 15 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to therapy and endocrinology, and can be used in treating patients suffering type 2 diabetes mellitus. That is ensured by a continuous exenatide delivery by implanting into a patient into an osmotic delivery device comprising an impermeable container, a semi-permeable membrane, an osmotic mechanism integrated into the container and adjoining the semi-permeable membrane, a piston adjoining the above osmotic mechanism; the above piston forms a movable seal with an inner surface of the container and divides the container into a first chamber comprising the osmotic mechanism, and a second chamber comprising a suspension formulation, and a diffusion adjustor. The suspension formulation contains a particle formulation containing exenatide particles having a diameter of less than 10 to 30 mcm. The delivery formulation contains a solvent specified in a group consisting of benzyl benzoate, lauryl lactate and lauryl alcohol, and polyvinylpyrrolidone polymer. The delivery formulation has a viscosity of approximately 10,000 poise to approximately 20,000 poise at 37°C. The continuous exenatide delivery in the therapeutic concentration is ensured for 5 days or less. The continuous exenatide delivery from the osmotic delivery device in a dose of exenaide of 10 mcg/day, 20 mcg/day, 30 mcg/day, 40 mcg/day, 60 mcg/day, and 80 mcg/day can be effected through at least three months.

EFFECT: method enables the effective treatment of the given pathology by the fast achievement and long maintenance of the exenatide concentration to be completed rapidly with no constant injections or oral administration.

15 cl, 20 tbl, 21 dwg, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to medicine, namely to oncology, and can be used for treatment of cerebral glioma. For this purpose combination of cannabinoids-tetrahydrocannabinol (THC) and cannabidiol (CBD) and non-cannabinoid chemotherapeutic agent is claimed. THC and CBD ratio constitutes from 5:1 to 1:5.

EFFECT: combination of anti-tumour medications provides efficient reduction of brain tumour volume due to selective death of transformed cells.

14 cl, 2 tbl, 8 dwg

FIELD: medicine.

SUBSTANCE: group of inventions refers to medical equipment. A device for the continuous analysis of a target substance in a body fluid sample comprises a sensitive unit with a subcutaneous sensor for obtaining the target substance information, a power source for power supply to the sensor and a data storage unit for the sensor data storage. The device data storage unit for the continuous analysis is detachably connected to the sensitive unit and comprises a storage container. The control unit of the device for the continuous analysis is configured to control the relevant data storage from the part of data storage in the storage container, when the storage unit is attached to the sensitive unit, and to control the data transmission from the storage container, when the storage container remote from the sensitive unit is attached to an external device. The system controlling the target substance in the body fluid sample comprises the device for continuous control and the external device which is provided with the storage containers for the relevant data storage as obtained from the sensor or from the storage container. The data storage unit and the external device are detachably connected.

EFFECT: using the group of inventions enables providing the more accurate transmission of the body fluid ingredients data to the external device.

15 cl, 11 dwg

FIELD: medicine.

SUBSTANCE: group of inventions refers to medical equipment and characterises versions of an undersized disposable syringe with an automatic destruction function. According to the first version, the syringe comprises a syringe cylinder, a piston rod and a locking element. The syringe cylinder has an inner surface forming the cavity, an open end and a distal end. The piston rod has a lock portion, a flange for applying the user's force, an elongated body, a hollow along this elongated body and a group of first teeth. The group of first teeth is formed inside the hollow on the elongated body and forms a group of projections facing in the distal direction and equally distributed along the major portion of the elongated body. The locking element slides inside the cavity along the above major portion of the elongated body; this locking element interacts with the inside of the syringe cylinder so that the locking element cannot be movable towards an open end of the syringe cylinder, and can interact with the piston rod so that the piston rod and the locking element can be movable together in the distal direction to the distal end of the syringe cylinder. The above hollow extends from the locking element to the above flange. The locking element is buried into one hollow of the elongated body of the piston rod.

EFFECT: inventions enable providing the piston fracture in the target direction by imbalances of the structural integrity between the reduced cross section and the remained portion of the piston.

42 cl, 19 dwg

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine, and may be used for unassisted drug injections by a patient. That is ensured by using a clamp for fat roll formation comprising control handles connected by an axle fixing rack gears and clamping branches. The clamping branches are rotation-fixed and replaceable. The clamp axle comprises an anti-rotating disk with mark symbols and a rotating disk with a window fixed when setting a required mark symbol of an injection region. What is also presented is a method for fat roll formation by the given clamp. The formed fold is height and thickness adjusted by holding it by fixed force upon completion of the injection. The injection region is fixed and alternated for the following injections.

EFFECT: invention enables safe injection by observing a fat roll formation technique and holding the roll throughout the drug injection by fixed and uniform force keeping hands free.

2 cl, 3 dwg, 2 ex

FIELD: medicine.

SUBSTANCE: endoscopic installation of a covered metal self-extending stent is performed into a lumen of the duodenum with a source of bleeding or an ulcerous wall defect. Applied is the stent with a diameter of an opening of not less than 22 mm. In order to perform installation the delivery device of the stent is passed behind the area of bleeding. After that the stent is placed in such a way that its funnel-shaped extended edges tightly rest against walls of the duodenum, creating a closed cavity between the proximal and distal edges of the stent.

EFFECT: method makes it possible to ensure reliable haemostasis, effective sealing of the area of the tubular organ wall defect and prevent its contact with physiological liquids due to which ensure the prevention of development of complications, accompanying the main disease.

2 cl, 1 ex, 2 dwg

FIELD: medicine.

SUBSTANCE: group of inventions relates to medical devices, containing highly-strong alloy, eventually subjected to degradation in human or animal organism, at adjustable degradation rate, without formation of emboli. Described is device for bone fixation, such as fixer, screw, plate, support or rod, made from alloy, as well as device for tissue fixation, such as staple, made from alloy. Dental implant or stent, made from alloy, is described.

EFFECT: alloy-containing devices possess required steel-associated properties, being simultaneously biodegradable.

22 cl, 8 ex

FIELD: medicine.

SUBSTANCE: invention relates to medical equipment, namely to suppository devices, applied against urine incontinence in women. A non-expandable intra-vaginal suppository device is made with a possibility to produce alternating pressure on the woman's urethra along its length, when introduced into the woman's vagina. The device has a top, a base and a lateral wall, extending between the top and base. The lateral wall, the top and the base form a closed outer periphery, determining the total area of the device. The device contains an internal part, in fact, closed by the top, base and lateral wall. The lateral wall contains a lower convex part, the middle section and a convex upper part. The convex upper part connects the base with the middle section, and the convex upper part connects the top with the middle section. The middle section has the maximal diameter, smaller than the maximal diameter of the convex lower and the convex upper part. The convex lower part and the convex upper part are made with a possibility to provide pressure on two different places on the woman's urethra, when the device is introduced into the woman's vagina. The suppository device is characterised by the length, measured along the longitudinal axis, shorter than 60 mm.

EFFECT: invention is suitable for the daily application, has a small size and, nevertheless, is sufficiently effective and more comfortable in application.

8 cl, 8 dwg

FIELD: medicine.

SUBSTANCE: invention relates to the field of medicine, namely to devices for the treatment of the vasculature and other ducts, which can be used for the treatment of the vasculature occlusion, as well as aneurisms, formed in the brain. A device for the treatment of the vasculature and ducts in an organism contains an elongated self-extending element, made with the possibility of extension from the first supply position into the second installation position. In the first position the elongated self-extending element is in a non-extended position and has the first diameter. In the second position the extending element is in an extended by radius position and has the second diameter, exceeding the first diameter. The elongated self-extending element contains a multitude of cellular structures. The elongated self-extending element has the proximal terminal section with the proximal end and a cylindrical section of the main case. Cellular structures on the cylindrical section of the main case pass on the circumference around the longitudinal axis of the elongated self-extending element. Cellular structures on the proximal terminal section do not pass along the entire circumference around the longitudinal axis of the elongated self-extending element. The proximal cellular structures on the proximal terminal section contain angle braces with the larger width than the angle braces of the cellular structures on the cylindrical section of the main case.

EFFECT: invention provides the improved device for the treatment of the vasculature and other ducts in the organism such as, for instance, aneurisms, stenoses, embolic obstruction, etc.

19 cl, 29 dwg

FIELD: medicine.

SUBSTANCE: lower lachrymal point is expanded. A probe is projected along a lower lachrymal duct all the way to the bone. A light guide is delivered through the expanded lower lachrymal duct all the way to the bone and fixed manually. A nasal cavity is visualised with an endoscope. Bone tissue of a lateral wall of the nasal cavity is burned through with endoscopically controlled laser light until the laser light appears in the nasal cavity. That implies using a diode laser at wave length 970 nm, emission power 6-7 Wt, in the continuous mode. An endoscopically controlled drain tube is inserted into the formed fistula through the nasal cavity by means of a plastic injector 10.01 mm long, 2 mm in diameter. The drain tube is 8.4 mm long. An external diameter of the cylindrical portion is 3 mm, whereas an internal diameter is 2 mm with the length of 6 mm. For the purpose of fixation in the lachrymal sac, an implanted end of the drain tube has deformable fletching elements 5 mm in diameter, 1 mm wide from each side, and 3.2-3.5 mm in flexion diameter. At the opposite side of the drain tube, there is a pad 5 mm in diameter fixed in the nasal cavity. Along the entire drain tube, there are grooves 0.25 mm wide, 8-8.1 mm long for additional outflow of the lachrymal fluid.

EFFECT: method enables preventing recurrent atresias of the formed fistulas between the lachrymal sac and nasal cavity by long-term postoperative drainage of the formed fistula.

2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to medicine, namely to implanted medical devices. A device for drug delivery includes an implanted intra-lumen framework, which has a luminal surface and abluminal surface; a multitude of through hollows in the intra-lumen framework, where each of the multiple through holes contains a composition, selected from the following groups. Compositions of a mTOR inhibitor and base structure, which has the configuration, which will make it possible for the mTOR inhibitor in the composition of the mTOR inhibitor to elute, mainly in the abluminal direction for seven (7) to one hundred and twenty (120) days, with the composition of the mTOR inhibitor containing a polymer in a combination with the mTOR inhibitor and the base structure containing a multitude of polymer layers with the absence of mTOR inhibitors; compositions of a phosphodiesterase III inhibitor and an upper covering structure, which has the configuration, making it possible for the phosphodiesterase III inhibitor in the composition of the phosphodiesterase III inhibitor to elute, mainly in the luminal direction for five (5) to sixty-one (61) day, with the composition of the phosphodiesterase III inhibitor containing the polymer in a combination with the phosphodiesterase III inhibitor, and the upper covering structure containing a multitude of polymer layers in the absence of the phosphodiesterase III inhibitor.

EFFECT: invention makes it possible to provide independent on each other rates of sirolimus and cistazol release, simultaneously providing the targeted delivery of each of the medications.

6 cl, 30 dwg, 7 tbl

FIELD: medicine.

SUBSTANCE: femoral artery is punctured on the right to place an introducer therein. The radial artery is punctured to connect a roller pump for arterial blood sampling. The subclavian or internal jugular vein is punctured to approach the coronary sinus to place a retro perfusion balloon. The retro perfusion balloon is inserted into a proximal segment of the great or middle cardiac vein. The balloon is inflated, and retro perfusion is performed at 20 ml/min accompanying the balloon angioplasty and/or stent implantation. The balloon is blown off after an antegrade blood flow is recovered.

EFFECT: method enables reducing a risk of intraoperative and postoperative complications, reducing a risk of haemorrhages, thromboses and ischemia of an extremity by puncturing the radial artery.

2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medical equipment and can be used for the replacement of involved natural human cardiac valves. A frame for a biological cardiac valve prosthesis comprises a tubular insert 2, which bears a flexible element 5 having flexible supports 6, each of which comprises two flexible beams 7. Each flexible beam 7 is provided with a loop-shaped element 16 positioned on heads 8 of the flexible beams 7 and coupling support stands 9 and bridges 13 mounted between two support stands 9 of the flexible element 5 from different flexible supports 6; each loop-shaped element 16 is provided with a seating surface 17 facing the vertical plane 11 passing through the central axis 12 of the frame; the support stands are mounted in relation to the above vertical plane 11; the seating surface 17 lies in a plane extending in parallel through the central axis of the frame with the support stands 9 being mounted symmetrically in relation to the vertical plane 11. The seating surfaces 17 of two flexible beams 7 from the same flexible support 6 are configured symmetrically in relation to the plane 11 passing through the central axis 12 of the frame.

EFFECT: increasing the reliability by reducing a rate of potential cusp cutting-through by fastening threads.

3 cl, 5 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medical equipment, namely to an implant delivery system to a segment of a body cavity, particularly to an expandable implant (e.g. stent) delivery systems. The stent delivery system comprises an expandable stent, an elongated inner element, a holding element and a coating. The stent has proximal and distal ends and a first fixing structure. The elongated inner element specifies a long axis. The holding element is fastened to the elongated inner element and comprises a second fixing structure configured to interact to the first fixing structure of the stent. The holding element is configured to move longitudinally in relation to the elongated inner element. The coating is mounted on the elongated inner element and configured to be arranged in the travelling position, wherein the coating covers the stent, and in the placing position, wherein the stent is opened at least partially. According to the second implementation, the system comprises a deformable holding ring surrounding the elongated element. The deformable holding ring sets a coating diameter so that if the coating is found in the travelling position, the deformable holding ring is compressed by the coating so that an outer end of the deformable holding ring is pressed into a proximal end of the stent, and after the coating is shifted into the placing position, the above outer end of the deformable holding ring is released from the coating contact to enable moving and opening the proximal end of the stent and releasing the above stent. According to the third embodiment, the system comprises an elongated element having a stent attachment section comprising a compressible material. In the travelling position, the coating compresses the stent so that the stent cells are pressed into the compressible material and entraps it, and in the placing position, which enables releasing the stent from the coating and providing the stent travelling into an expanded configuration released from the compressible material. According to the fourth embodiment, the system comprises the elongated inner element, the expandable stent, the generally ring holder and the coating. The stent tightly adjoins the distal end of the elongated inner element. The holder is fastened to the inner element and has a size adequate for the detachable connection with the expandable stent and for the longitudinal travel along the elongated inner element. The coating is mounted on the elongated inner element and configured to travel from the travelling position, wherein the coating covers the stent, into the placing position, wherein the stent is opened at least partially.

EFFECT: invention enables holding the stent on a catheter, even if a major portion of the stent is opened by driving back the coating, and enables the re-closing of the stent even after the major portion of the stent is opened by driving back the coating that makes it possible to adjust the stent position after it is partially released.

23 cl, 16 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine. There are described implanted devices with various versions of biologically active ingredient loading with the version selectable and applicable for creating a prolonged-release profile or a release profile having a low initial ejection of the biologically active ingredient from the implanted device.

EFFECT: there are described the implanted devices with various versions of biologically active ingredient loading.

11 cl, 2 dwg

FIELD: medicine.

SUBSTANCE: group of inventions relates to medical diagnostics. Method of determining degree of vessel narrowing contains stages at which obtained are: sequence of first pressure measurements P1 and sequence of respective first rate measurements U1 in first location inside vessel, sequence of second pressure measurements P2 and sequence of respective second rate measurements U2 in second location inside vessel. Wave rate c in fluid medium is determined for each location depending on square of pressure change divided by square of respective rate change. For first location change of direct pressure is determined depending on the sum of pressure change and rate change. For second location change of direct pressure is determined depending on the sum of pressure change and rate change. Reserve of separated direct flow, representing drop of pressure through target area is determined, with said drop of pressure indicating degree of local narrowing or compression of vessel between said first location and second location. Device for determining degree of vessel narrowing is described.

EFFECT: inventions provide measurement of localised flow restriction.

14 cl, 6 dwg

Up!